Emergent BioSolutions (EBS)

Executive Summary

Emergent BioSolutions is a specialty biopharmaceutical company focused on the development, manufacture, and commercialization of medical countermeasures for public health threats, including chemical, biological, radiological, and nuclear (CBRN) agents and emerging infectious diseases. The company's portfolio includes marketed products such as BioThrax (anthrax vaccine), ACAM2000 (smallpox vaccine), and VIGIV (vaccinia immune globulin), which are primarily procured by U.S. government entities like HHS and DoD. Additionally, Emergent operates a contract development and manufacturing organization (CDMO) business, providing biologics manufacturing services to other pharmaceutical companies. Despite facing operational challenges in the past, including manufacturing issues during the COVID-19 pandemic, the company remains a key supplier for the Strategic National Stockpile, with a pipeline of 48 drug candidates spanning from pre-clinical to Phase 3 stages. Recent financial performance has been pressured by declining government orders and CDMO revenue, but the company is focusing on cost restructuring and diversification into new areas such as opioid overdose reversal and emerging infectious diseases.

Upcoming Catalysts (preview)

• Q3 2026BARDA contract award for anthrax vaccine (BioThrax/AVP-21D) procurement80% success
• Q4 2026Strategic partnership or expansion of CDMO business with new client agreements60% success
• H1 2027FDA approval or emergency use authorization for next-generation smallpox/MPOX vaccine (e.g., MVA-BN or AV7909)70% success